132289-57-7

Usage

Uses

Used in Chemical Synthesis:
N-METHOXY-N-METHYL-2-METHOXYACETAMIDE is used as a solvent in chemical synthesis for its capacity to dissolve a wide range of substances, facilitating various chemical reactions and processes.
Used in Pharmaceutical Production:
In the pharmaceutical industry, N-METHOXY-N-METHYL-2-METHOXYACETAMIDE serves as a solvent, aiding in the manufacturing of drugs by enabling the dissolution of active pharmaceutical ingredients and other components.
Used as a Cleaning Agent:
Due to its ability to dissolve diverse materials, N-METHOXY-N-METHYL-2-METHOXYACETAMIDE is utilized as a cleaning agent in various settings, including industrial applications where the removal of residues and contaminants is required.
Used in High-Temperature Processes:
The high boiling point and low volatility of N-METHOXY-N-METHYL-2-METHOXYACETAMIDE make it an ideal solvent for processes that demand elevated temperatures, ensuring that the solvent remains stable and effective under such conditions.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 625-45-6 2-methoxyacetic acid 
• 38870-89-2 Methoxyacetyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 31059-08-2 1-(1H-imidazol-1-yl)-2-methoxyethanone 

Downstream Products

• 50-00-0 formaldehyd 
• 57270-75-4 methoxy-acetic acid methylamide 
• 26771-69-7 2-methoxy-1-(4-(trifluoromethyl)phenyl)ethan-1-one 
• 505052-91-5 2,4-Dimethoxy-6-(3-methoxy-2-oxo-propyl)-benzoic acid methyl ester 
• 166526-05-2 1-cyclopropyl-2-methoxyethanone 
• 945844-28-0 1-methoxy-4-phenylbut-3-yn-2-one 
• 32904-95-3 4-methoxy-1-phenylbutane-1,3-dione 

Relevant academic research and scientific papers

Conformational preferences for some 2-substituted N-methoxy-N- methylacetamides through spectroscopic and theoretical studies

The analysis of the IR carbonyl band of the 2-substituted N-methoxy-N-methylacetamides Y-CH2C(O)N(OMe)Me (Y = F 1, OMe 2, OPh 3, Cl 4), supported by B3LYP/6-311++G(3df, 3pd) calculations along with the NBO analysis for 1-4, indicated the existence of cis-gauche conformers i.e. (c) and (g) for 1 and 3, (c1, c2) and (g1, g 2) for 2, and (c) and (g1, g2) for 4. In the gas phase, the g conformer population prevails over the c one, for 1 and 3, the (c1 + c2) population prevails over the (g1 + g2) one for 2, and the (g1 + g2) conformer population is more abundant than (c) one for 4. In n-hexane solution, the cis conformer is more abundant for 1-3. The occurrence of Fermi resonance in the νCO region, in n-hexane, precludes the estimative of relative populations of the (c, g1, g2) conformers for 4. The SCI-PCM calculations agree with the solvent effect on the νCO band component relative intensities for 1-3. NBO analysis showed that the n N → πco* orbital interaction is the main factor which stabilizes the gauche (g, g1, g2) conformers for 1-4 into a larger extent relative to the cis (c, c1, c2) ones. The nY → πco *, σC-Y → πco*, πco → σC-Y* and πco* → σC-Y* orbital interactions still contribute, but into a minor extent for the stabilization of the gauche conformers relative to the cis ones. The existence of some pyramidalization at the nitrogen atom of the Weinreb amides 1-4 is responsible for the occurrence of Yδ-(4)?Oδ-(9) and Y δ-(4)?Nδ-(7) short contacts in the gauche (g, g1, g2) conformers, which originates strong repulsive Coulombic interactions, acting in opposition to the large orbital stabilization of the gauche conformer with respect to the cis one. Therefore, a delicate balance of the Coulombic and orbital interactions seems to be responsible for the observed stabilization of the gauche (g, g1, g2) and cis (c, c1, c2) conformers, both in the gas phase and in the solution for 1-4. However, the cis conformer predominance, in non polar solvents, for the 2-substituted N-methoxy-N-methyl acetamides 1-3, bearing in α first raw (fluorine and oxygen) atoms, is in the opposite direction to the gauche conformer preference for the corresponding 2-substituted N,N-dialkyl-acetamides.

Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: Implications for a greater signaling diversity in bacterial species

Talking bacteria: The combination of NMR spectroscopy and 4,5-dihydroxy-2,3-pentanedione (DPD) homologue analysis reveals that DPD, a bacterial signaling compound in the autoinducer-2 (AI-2) class (see scheme), exists as a much more complex structural array of molecules than previously appreciated. This finding suggests the existence of a larger bacterial chemical signaling language than previously thought. Copyright

Enantioselective Iridium-Catalyzed Allylation of Acetylenic Ketones via 2-Propanol-Mediated Reductive Coupling of Allyl Acetate: C14-C23 of Pladienolide D

Highly enantioselective catalytic reductive coupling of allyl acetate with acetylenic ketones occurs in a chemoselective manner in the presence of aliphatic or aromatic ketones. This method was used to construct C14-C23 of pladienolide D in half the steps previously required.

HETEROCYCLIC COMPOUND

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME

The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.